Skip to content

GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug – Endpoints News

GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug  Endpoints NewsMerck to buy Acceleron for about $11.5 billion in rare-disease drugs push  CNBCMerck to acquire Acceleron Pharma in $11.5 billion deal  CNBC TelevisionMerck to Buy Rare-Disease Firm Acceleron for $11.5 Billion  Yahoo FinanceMerck buying Acceleron Pharma in $11.5B deal  Fox BusinessView Full Coverage on Google News

Leave a Reply

Your email address will not be published. Required fields are marked *